Abstract: The disclosed technology teaches a method for customers of an organization to perform configuration at runtime for authentication journeys used by the customer's users, to simplify authentication trees, and to delegate configuration to the customer's administrators, wherein an authentication tree implements an authentication journey, the authentication tree including authentication nodes and edges connecting the authentication nodes. The method includes configuring an editable script and an authentication node used in the authentication tree in response to a user invocation of the authentication journey by executing a factory method that applies configuration parameters to the editable script and to parameters used to access an API.

Abstract: The invention relates to proteins that contain the CD4 domain 1 and the CD4 domain 2 (CD4 D1D2), wherein the CD4 D1D2 contains one or more mutations compared to wild-type human CD4 D1D2, and to methods of using the proteins for treating a human immunodeficiency virus (HIV) infection in a subject.

Abstract: The invention relates to proteins that contain the CD4 domain 1 and the CD4 domain 2 (CD4 D1D2), wherein the CD4 D1D2 contains one or more mutations compared to wild-type human CD4 D1D2, and to methods of using the proteins for treating a human immunodeficiency virus (HIV) infection in a subject.

Abstract: The disclosed technology teaches a method for customers of an organization to perform configuration at runtime for authentication journeys used by the customer's users, to simplify authentication trees, and to delegate configuration to the customer's administrators, wherein an authentication tree implements an authentication journey, the authentication tree including authentication nodes and edges connecting the authentication nodes. The method includes configuring an editable script and an authentication node used in the authentication tree in response to a user invocation of the authentication journey by executing a factory method that applies configuration parameters to the editable script and to parameters used to access an API.

Abstract: The present invention provides scaffolded antigens that have demonstrated improved biochemical and immunogenic properties. The invention also provides engineered SARS-CoV-2 immunogens that contain a modified receptor-binding domain (RBD) sequence. Also provided in the invention are vaccine compositions that contain the scaffolded antigens, including the engineered RBD polypeptides that are fused to the scaffold proteins described herein. The invention also provides methods of using such vaccine compositions in various therapeutic applications, e.g., for preventing or treating SARS-CoV-2 infections.

Abstract: The invention relates to proteins that contain the CD4 domain 1 and the CD4 domain 2 (CD4 D1D2), wherein the CD4 D1D2 contains one or more mutations compared to wild-type human CD4 D1D2, and to methods of using the proteins for treating a human immunodeficiency virus (HIV) infection in a subject.

Abstract: Disclosed herein are single nucleic acid constructs comprising a vector, wherein the vector comprises: a first nucleic acid sequence, wherein the first nucleic acid sequence comprises one or more antigenic sequences of interest, one or more spacer sequences and one or more hydrophobic anchor sequences, operably linked to a first transcriptional control element; a second nucleic acid sequence, wherein the second nucleic acid sequence comprises one or more pathogen-associated molecular pattern (PAMP) sequences operably linked to a second transcriptional control element; a third nucleic acid sequence, wherein the third nucleic acid sequence comprises one or more cell surface receptor binding sequences operably linked to a third transcriptional control element; and a selectable marker. Also described herein, are methods of making the single nucleic acid constructs and methods of administering the single nucleic acid constructs for the treatment or prevention of infections and cancer.

Abstract: Disclosed herein are single nucleic acid constructs comprising a vector, wherein the vector comprises: a first nucleic acid sequence, wherein the first nucleic acid sequence comprises one or more antigenic sequences of interest, one or more spacer sequences and one or more hydrophobic anchor sequences, operably linked to a first transcriptional control element; a second nucleic acid sequence, wherein the second nucleic acid sequence comprises one or more pathogen-associated molecular pattern (PAMP) sequences operably linked to a second transcriptional control element; a third nucleic acid sequence, wherein the third nucleic acid sequence comprises one or more cell surface receptor binding sequences operably linked to a third transcriptional control element; and a selectable marker. Also described herein, are methods of making the single nucleic acid constructs and methods of administering the single nucleic acid constructs for the treatment or prevention of infections and cancer.

Abstract: The invention provides methods and materials for identifying agents for preventing and/or treating anthrax and similar diseases. Embodiments provide strains and model systems for studying non-lethal and lethal exposure to anthrax and similar disease vectors. Embodiments provide materials and methods for using the strains and model systems for differential profiling, such as proteomic profiling, such as differentiation phosphorylation profiling, to target identification and therapeutics discovery and development. Embodiments provide pharmaceutically acceptable compositions, and methods for using them to prevent and/or treat anthrax and similar diseases comprising an agent that decreases the activity of caspase ¼, such as YVAD, and/or an agent that increases the phosphorylation of AKT, such as IB-MECA or Cl-IB-MECA, together with, in particular embodiments, an antibiotic, such as ciprofloxacin. Kits comprising the same are provided as well, among other things.

Abstract: The present invention provides compositions and methods for detecting, treating, and preventing microbial infection, especially infection caused by Bacillus anthracis (“anthrax”).

Abstract: The present invention is directed to a business intelligence monitor method and system. Business intelligence indicators are monitored by generating a monitoring repository through selecting functions from a collection of functions, for receiving the business intelligence indicators as inputs. The thresholds for the business intelligence indicators are then established to define the states for the business intelligence indicators. Each state of the business intelligence indicators is assigned an associated priority. The monitoring repository is updated by retrieving a current value for each of the business intelligence indicators from a data source, thereby determining the state for each of the business intelligence indicators based on the current value. A report based on the updated monitoring repository is then created.

Abstract: The claimed invention describes methods and apparatuses for manufacturing nano-aerosols and nano-structured materials based on the neutralization of charged electrosprayed products with oppositely charged electrosprayed products. Electrosprayed products include molecular ions, nano-clusters and nano-fibers. Nano-aerosols can be generated when neutralization occurs in the gas phase. Neutralization of electrospan nano-fibers with molecular ions and charged nano-clusters may result in the formation of fibrous aerosols or free nano-mats. Nano-mats can also be produced on a suitable substrate, forming efficient nano-filters.

Abstract: The invention contemplates a method for recognition of proteins and other biological molecules by imaging morphology, size and distribution of crystalline and amorphous dry residues in droplets (further referred to as “crystallization pattern”) containing predetermined amount of certain crystal-forming organic compounds (reporters) to which protein to be analyzed is added. It has been shown that changes in the crystallization patterns of a number of amino-acids can be used as a “signature” of a protein added. It was also found that both the character of changer in the crystallization patter and the fact of such changes can be used as recognition elements in analysis of protein molecules.

Abstract: The invention involves developing and stabilizing cultivating droplets within a matrix of a porous medium. A cultivation medium may be selected, prepared and mixed with a surfactant. Where cells are desired to be cultured in droplets, cells may be added. The mixture may be converted into cultivating droplets. The cultivating droplets may be stabilized by introducing them to a porous medium. The porous medium may contain hydrophobic particles. Stabilized, cultivating droplets having one or more cells may form an aseptic microenvironment for the concentrated growth of cells.

Abstract: Analytes using an active assay may be detected by introducing an analyte solution containing a plurality of analytes to a lacquered membrane. The lacquered membrane may be a membrane having at least one surface treated with a layer of polymers. The lacquered membrane may be semi-permeable to nonanalytes. The layer of polymers may include cross-linked polymers. A plurality of probe molecules may be arrayed and immobilized on the lacquered membrane. An external force may be applied to the analyte solution to move the analytes towards the lacquered membrane. Movement may cause some or all of the analytes to bind to the lacquered membrane. In cases where probe molecules are presented, some or all of the analytes may bind to probe molecules. The direction of the external force may be reversed to remove unbound or weakly bound analytes. Bound analytes may be detected using known detection types.

Abstract: A trim assembly comprises a substrate member including a moveable panel integrally formed in the substrate and moveable between an open and closed position. A flexible skin overlies at least a portion of the substrate member and is integrally coupled to the substrate. The substrate and flexible skin are configured to define a cavity having an opening. The cavity opening is accessible when the moveable panel is in the open position. A resilient foam pad is positioned within the cavity to provide a soft feel to the trim assembly. The foam pad is inserted into the cavity using a tool that pulls a vacuum and compresses the foam pad. The foam pad is inserted into the cavity and the vacuum is released thereby expanding the foam pad to fill the cavity. The tool is removed and the moveable panel is moved to and secured in the closed position.

Abstract: A trim assembly comprises a substrate member including a moveable panel integrally formed in the substrate and moveable between an open and closed position. A flexible skin overlies at least a portion of the substrate member and is integrally coupled to the substrate. The substrate and flexible skin are configured to define a cavity having an opening. The cavity opening is accessible when the moveable panel is in the open position. A resilient foam pad is positioned within the cavity to provide a soft feel to the trim assembly. The foam pad is inserted into the cavity using a tool that pulls a vacuum and compresses the foam pad. The foam pad is inserted into the cavity and the vacuum is released thereby expanding the foam pad to fill the cavity. The tool is removed and the moveable panel is moved to and secured in the closed position.

Abstract: The present invention pertains to genetic screening methods and related cells and genetic constructs. In particular, the invention relates to a method of screening cells for an alteration, typically an amplification, in the copy number of a nucleic acid of interest using an amplifiable nucleic acid linked to a reporter nucleic acid; a method of screening cells for increased expression of a polypeptide of interest derived from the nucleic acid of interest; and related cells and genetic constructs. The method allows for high throughput screening of recombinant cells expressing a polypeptide or protein of interest and, in particular, for screening of cells expressing the polypeptide or protein of interest at elevated levels.

Abstract: A treatment for the effects of biological threat agents, such as smallpox virus or anthrax, to be administered either post-infection or as prophylaxis for infection, comprises administration of IFN-&agr;, IFN-&ggr;, or the cell wall of the bacteria B. alcalolophilus, E. faecium, S. caseolyticus, or B. stearothermoohilus or a combination of these components. Additionally, the treatment comprises a combination of antibodies, such as antibodies to heat-inactivated anthrax microbes or to the anthrax Protective Antigen, and antibiotics, such as ciprofloxacin. The treatment also comprises the peptidoglycan, lipoteichoic acid, or muramyl peptide fraction of bacterial cell walls, either alone or in combination with the cytokines, antibodies, and antibiotics provided. These treatments for smallpox and anthrax are administered as an inhalation preparation and therefore avoid the toxic effects of the higher doses of these components.

Abstract: The present invention is directed to a business intelligence monitor method and system. The method, leveraging the functionality of an existing business information-reporting infrastructure, includes the step of authoring a monitor document derived from a determined methodology by creating one or more intelligence indicators, establishing thresholds for the one or more created intelligence indicators and selecting status definitions for the established thresholds. The method further includes the step of building a report guided by the authored monitor document by retrieving data from a data source for each of the one or more intelligence indicator, assigning statuses to each of the one or more intelligence indicators based on the retrieved data and generating a report incorporating one or more intelligence indicators, retrieved data and assigned statuses.